01 — At a Glance
The Content Dinosaur That Decided to Become a Healthcare AI Startup
- 52-Week High / Low₹3,079 / ₹1,336
- Q3 FY26 Revenue₹182 Cr
- Q3 FY26 PAT₹40.8 Cr
- TTM EPS₹101
- Annualised EPS (Q3 × 4)₹82.9
- Book Value / Share₹287
- Price to Book5.26x
- ROCE40.9%
- ROE30.5%
- Operating Margin32%
Flash Summary: MPS posted Q3 FY26 PAT of ₹40.8 crore (up 0.22% QoQ, which is basically flat). The TTM EPS is ₹101. Stock is up 27% in 5 years but down 47% in the last 12 months—classic value trap material. Then, just as the market was busy writing the obituary, MPS announced it acquired Unbound Medicine (USA) for $16.5M, positioning itself as a healthcare AI platform company. The board called it “transformative.” The market called it a 24% 1-year return drop. You be the judge.
02 — Introduction
From Editing Books to Teaching Doctors: The Pivot Nobody Expected
MPS Ltd is what happens when a company realizes that helping publishers typeset textbooks is a commodity business. So they diversified into learning platforms, eLearning solutions, digital content creation—basically building stuff on top of stuff on top of content. For 15+ years, this worked.
Then the AI explosion hit. And MPS woke up and realized that the future of learning isn’t “content that you pay ₹599 for,” but rather “intelligent platforms that cost hospitals ₹50 lakh annually and save clinicians five hours per week by reducing admin burden.”
Enter: Unbound Medicine. Founded in 1999, it’s a healthcare knowledge management platform trusted by 1,000+ hospitals and 500+ healthcare organizations globally. Revenue: ~$8.88 million in FY24. EBITDA margin: 14%. The platform serves medical professionals, nursing students, and healthcare facilities with clinical lookup tools, drug databases, and interactive learning. MPS just acquired 100% for $16.5 million (~₹138 crores) and immediately started talking about margin expansion, cross-selling through its existing network, and international geographic expansion into Southeast Asia, Middle East, Europe, and Australia.
This is not a short-term play. This is a pivot. And the market absolutely hates uncertainty in pivots—hence the -47% return in 12 months.
What the Q3 numbers won’t tell you: MPS raised ₹42 crores of debt to fund the acquisition. The CFO called it “very comfortable.” The CEO also confirmed in the concall that Unbound’s founder (Bill Detmer) is now a “strategic advisor” at a few hours per week, while the CTO, Sales, Product, and Marketing leadership are all staying. Key talent retention = good signal. Phantom equity given to Unbound management = skin in the game. These are the details that matter more than the headline numbers.
03 — Business Model: WTF Do They Even Do? (Now)
Three Businesses Walking Into a Bar. One Is Losing Relevance.
MPS has three business segments (though after the Unbound acquisition, it’s really four, which they haven’t reorganized yet):
Content Solutions (53% of revenue, FY24): They create, edit, design, and deliver digital and print content for educational publishers, academic institutions, and research organizations. Think: you’re Penguin Random House and you need someone to transform your PDF into an interactive ebook. MPS does that. Revenue: ₹149 crore (FY25). This is stable, profitable, but growing slowly. It’s your grandfather’s reliable 8% YoY growth business.
Platform Solutions (23% of revenue): SaaS platforms for publishing workflows—manuscript submission, peer review, hosting, identity management. Companies like Springer, Elsevier, and academic journals use their tech. Growing faster (15%+) but smaller scale. Margins are healthier because it’s recurring revenue.
eLearning Solutions (24% of revenue): Custom learning programs, microlearning, gamification, mobile learning for corporate training. Highest growth segment (20%+), but most commoditized. Anyone with a learning management system looks like MPS here.
And now, Unbound Medicine (≈ new 4th vertical): Healthcare knowledge management platform. Subscription-based. 97% retention rate. Low customer concentration (largest customer = <$300k annually). Early forecast: ₹138 crore acquisition → ₹42 crore debt raised → 14% EBITDA margins today → 20s% margins next quarter → 30% margins by Q4 FY27 exit (as per management guidance in the concall).
Cultural reference alert: This is like a dhaba owner suddenly learning sushi. Content Solutions was the dosa. Now they’re trying to add ramen (Unbound Medicine) to the menu. The kitchen might handle it, but the customer is confused about what you’re actually selling.
04 — Financials Overview
Q3 FY26: Flatline Earnings Wrapped in Optimistic Language
Result type: Quarterly Results | Q3 FY26 EPS: ₹20.75 | Q1 EPS: ₹17.29, Q2 EPS: ₹18.78 | Avg Q1–Q3 EPS: (₹17.29+₹18.78+₹20.75)/3 = ₹18.94 | Annualised EPS: ₹75.76
| Metric (₹ Cr) |
Q3 FY26
Dec 2025 |
Q3 FY25
Dec 2024 |
Q2 FY26
Sep 2025 |
YoY % |
QoQ % |
| Revenue | 182 | 186 | 194 | -2.08% | -6.19% |
| Operating Profit | 58 | 60 | 60 | -3.33% | -3.33% |
| Operating Margin % | 32% | 32% | 31% | 0 bps | +100 bps |
| PAT | 36 | 41 | 55 | -12.20% | -34.55% |
| EPS (₹) | 20.75 | 23.80 | 32.41 | -12.81% | -36.00% |
Translation for humans: Q3 was weak. Revenue down 2% YoY and down 6% QoQ. PAT down 12% YoY and down 35% QoQ. EPS down 13% YoY. This is called “losing momentum.” The margin held steady at 32% only because management cut costs faster than revenue shrunk. This is not a growth story anymore—it’s a profitability-under-pressure story. Now throw in the Unbound acquisition announcement (which happened at the end of January), and suddenly the market has a “turnaround” narrative to digest. The stock tanked 24% over 12 months anyway, so the market is clearly skeptical.
💬 When a company posts weak organic earnings and then announces a “transformative” acquisition, is it a strategic pivot or a distraction play? What’s your instinct telling you?
05 — Valuation: Fair Value Range
Pricing a Business in Transition (i.e., Guessing)
